Gilead Sciences, Inc.
GILD Healthcare Drug Manufacturers General
Gilead Sciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $29.4 billion, up 2.40% from fiscal 2024. In the quarter to June 2026, revenue grew 10.2%, EPS fell 638.2%, free cash flow grew 376.8% and total debt rose 5.21%, each against the same quarter a year earlier. Member of the S&P 500 and Nasdaq 100; dividend growth for ten consecutive years.
Follow GILD
Gilead Sciences, Inc. (GILD) Revenue
Gilead Sciences, Inc.'s revenue for fiscal 2025 was $29.4B, unchanged from fiscal 2024. Over the twelve months to 30 June 2026 it was $30.5B. Over the past ten years it has ranged from $22.1B (fiscal 2018) to $32.6B (fiscal 2015); the current reading is higher than 82% of that period. Gilead Sciences, Inc. ranks 13th of 18 Drug Manufacturers General companies by revenue.
Revenue, annual
Embed this chart
Annual newest first
| Period | Revenue | Change |
|---|---|---|
| FY2025 | $29.4B | 2.40% |
| FY2024 | $28.8B | 6.04% |
| FY2023 | $27.1B | (0.60%) |
| FY2022 | $27.3B | (0.09%) |
| FY2021 | $27.3B | 10.60% |
| FY2020 | $24.7B | 9.98% |
| FY2019 | $22.4B | 1.46% |
| FY2018 | $22.1B | (15.24%) |
| FY2017 | $26.1B | (14.09%) |
| FY2016 | $30.4B | (6.89%) |
Quarterly newest first
| Period | Revenue | Change |
|---|---|---|
| Jun 2026 | $7.8B | 12.11% |
| Mar 2026 | $7.0B | (12.18%) |
| Dec 2025 | $7.9B | 2.01% |
| Sep 2025 | $7.8B | 9.70% |
| 42 more quarters | Free account |
Against its own ten years
Revenue against peers
| Company | Revenue |
|---|---|
| MRK Merck & Co., Inc. compare | $66.6B |
| PFE Pfizer Inc. compare | $63.7B |
| AZN AstraZeneca PLC compare | $61.4B |
| NVS Novartis AG compare | $56.7B |
| NVO Novo Nordisk A/S compare | $51.5B |
| BMY Bristol Myers Squibb Company compare | $49.2B |
| GSK GSK PLC Sponsored ADR compare | $44.5B |
| AMGN Amgen Inc. compare | $38.1B |
| GILD Gilead Sciences, Inc. | $30.5B |
What Revenue is
Revenue tells an investor how much a company brought in from selling its goods and services over a period, before any costs are taken out.
Reported line item
More on GILD
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement